Pharmaceutical Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently US Food and Drug Administration (FDA)-approved migraine drug Symbravo, and the UK’s AstraZeneca announced positive Phase III trial results for its breast cancer candidate camizestrant. US biotech giant Amgen revealed it is pressing ahead with its $200 million investment in Indian technology center. US pharma major Eli Lilly attracted attention with its licensing deal for Organovo’s FXR program and announcing the release of new dosages and prices for its blockbuster obesity drug Zepbound. 2 March 2025